Table 2.
Comparison of p16, p53, and Ki-67 expression according to grades and stages.
| Total N (%) | p16 | p Value | p53 | Ki-67 | p Value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative, N (%) | Weak, N (%) | Moderate, N (%) | Strong, N (%) | Negative, N (%) | Positive, N (%) | p Value | Low Index, N (%) | High Index, N (%) | |||||
| Diagnosis | Papillary UC | 30 (48.4%) |
13 (21.0%) |
1 (1.6%) |
7 (11.3%) |
9 (14.5%) |
26 (41.9%) |
4 (6.5%) |
23 (37.1%) |
7 (11.3%) |
|||
| Non-papillary UC | 32 (51.6%) |
15 (24.2%) |
2 (3.2%) |
4 (6.5%) |
11 (17.7%) |
27 (43.5%) |
5 (8.1%) |
18 (29.0%) |
14 (22.6%) |
||||
| Total | 62 (100%) |
28 (45.2%) |
3 (4.8%) |
11 (17.7%) |
20 (32.3%) |
0.69 | 53 (85.5%) |
9 (14.5%) |
0.54 | 41 (66.1%) |
21 (33.9%) |
0.07 | |
| Grade | High grade | 34 (54.8%) |
14 (22.6%) |
1 (1.6%) |
10 (16.1%) |
9 (14.5%) |
29 (46.8%) |
5 (8.1%) |
25 (40.3%) |
9 (14.5%) |
|||
| Low grade | 28 (45.2%) |
14 (22.6%) |
2 (3.2%) |
1 (1.6%) |
11 (17.7%) |
24 (38.7%) |
4 (6.5%) |
16 (25.8%) |
12 (19.4%) |
||||
| Total | 62 (100.0%) |
28 (45.2%) |
3 (4.8%) |
11 (17.7%) |
20 (32.3%) |
0.24 | 53 (85.5%) |
9 (14.5%) |
0.06 | 41 (66.1%) |
21 (33.9%) |
0.69 | |
| Stage | Stage pT1 | 32 (51.6%) |
15 (24.2%) |
0 (0.0%) |
8 (12.9%) |
9 (14.5%) |
27 (43.5%) |
5 (8.1%) |
24 (38.7%) |
8 (12.9%) |
|||
| Stage pT2 | 30 (48.4%) |
13 (21.0%) |
3 (4.8%) |
3 (4.8%) |
11 (17.7%) |
26 (41.9%) |
4 (6.5%) |
17 (27.4%) |
13 (21.0%) |
||||
| Total | 62 (100.0%) |
28 (45.2%) |
3 (4.8%) |
11 (17.7%) |
20 (32.3%) |
0.13 | 53 (85.5%) |
9 (14.5%) |
0.54 | 41 (66.1%) |
21 (33.9%) |
0.1 | |